Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company focused on medicines for HIV, viral hepatitis, COVID‑19, cancer and inflammation. The GILD news feed highlights how the company’s research, collaborations and policy decisions translate into clinical programs, regulatory milestones and access initiatives across these therapeutic areas.
Investors and healthcare observers following GILD news will see regular updates on Gilead’s HIV portfolio, including clinical trial readouts such as the Phase 3 ARTISTRY‑1 and ARTISTRY‑2 studies of an investigational single‑tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. News also covers developments related to lenacapavir as a long‑acting option for HIV prevention and treatment, as well as agreements affecting key products like Biktarvy, including patent settlements disclosed by the company.
Oncology and cell therapy news is another major theme. Through Kite, a Gilead company, GILD‑related releases feature data on Yescarta for relapsed or refractory large B‑cell lymphoma, next‑generation bicistronic CAR T‑cell candidates KITE‑753 and KITE‑363 for B‑cell lymphomas, and anitocabtagene autoleucel (anito‑cel) for relapsed or refractory multiple myeloma. Updates often include efficacy and safety results from pivotal and early‑stage trials, as well as details on collaborations such as the partnership with Arcellx on anito‑cel and the research collaboration with OncoNano Medicine on ON‑BOARD encapsulation technology.
Gilead news also reflects broader corporate and policy activity, including agreements with the U.S. government related to drug pricing and access, philanthropic grants from the Gilead Foundation for metastatic breast cancer support, leadership appointments, investor conference presentations and quarterly financial announcements. Bookmark this page to monitor how these scientific, commercial, governance and access‑related developments shape the ongoing story of GILD.
Gilead Sciences reported a strong Q2 2022, with total revenue rising 1% to $6.3 billion. Noteworthy product sales include Biktarvy, which surged 28% year-over-year to $2.6 billion, and oncology sales, which grew 71% to $527 million. However, diluted EPS decreased to $0.91 from $1.21 due to higher IPR&D expenses from an upfront payment of $300 million. Gilead's updated full-year guidance anticipates total product sales between $24.5 billion and $25.0 billion, and non-GAAP EPS between $6.35 and $6.75.
Gilead Sciences (GILD) has announced positive interim results from the ALLIANCE trial, showing that Biktarvy is effective for HIV patients with HBV coinfection. The trial demonstrated superior suppression of HBV DNA with Biktarvy compared to an alternative regimen. Additionally, data from five years of two Phase 3 studies revealed no treatment failures due to resistance. Overall, 99% of participants maintained an undetectable viral load. These findings highlight Biktarvy's potential as a long-term treatment option for individuals with HIV.
AlloVir (ALVR) announced a registered direct offering to sell 27,458,095 shares at $4.61 each, raising approximately $126.6 million, expected to close around July 28, 2022. The proceeds will fund ongoing Phase 3 trials for posoleucel, aimed at treating severe infections in immunocompromised patients. AlloVir plans to use the funds for trial completion, regulatory submissions, and R&D. As of June 30, 2022, the company had $172.7 million in cash. The offering is made without an underwriter and involves participation from new and existing investors, including Kite (GILD).
Kite, a Gilead Company (GILD), received a positive opinion from the European Medicines Agency (EMA) for Tecartus (brexucabtagene autoleucel) to treat adults over 26 with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This CAR T-cell therapy could address the significant unmet need in this patient population, where median overall survival is approximately eight months. The European Commission will review the opinion, with a decision expected soon. In clinical trials, Tecartus showed a 71% complete remission rate and a median overall survival of over two years for treated patients.
Gilead Sciences (GILD) announced that the European Commission's Committee for Medicinal Products for Human Use (CHMP) has recommended granting full Marketing Authorization for Veklury (remdesivir) in the EU. Initially authorized in July 2020 for COVID-19 treatment in hospitalized patients, the approval expands its use to non-hospitalized adults at risk for severe COVID-19. Veklury remains the only direct-acting antiviral with this full authorization in the EU. The decision is based on robust data confirming Veklury's efficacy against SARS-CoV-2 variants.
Gilead Sciences (NASDAQ: GILD) announced its participation in the 24th International AIDS Conference (AIDS 2022), held from July 29-August 2, 2022, in Montreal, Canada. The company aims to share updates on innovative initiatives and scientific findings regarding HIV treatment and prevention. Notable presentations include results from Phase 3 trials of Biktarvy and new data on investigational compounds like lenacapavir and vesatolimod. Gilead emphasizes collaboration with the global HIV community to improve health outcomes and drive towards ending the epidemic.
Gilead Sciences (NASDAQ: GILD) announced an $85 million contribution to the
Gilead Sciences announced a new joint procurement agreement (JPA) with the European Commission to ensure equitable access to Veklury (remdesivir) for COVID-19 patients across the EU and EEA. This agreement, effective for 12 months with a possible 6-month extension, follows the expiration of the original JPA. Veklury is crucial as it is the only antiviral licensed in this region for treating COVID-19 patients requiring supplemental oxygen. Positive results from clinical trials have increased its indications, reinforcing its role as a key treatment in combating COVID-19.
Gilead Sciences (Nasdaq: GILD) will release its Q2 2022 financial results on August 2, after market close. A webcast discussing the results will be held at 4:30 p.m. Eastern Time that same day. Gilead is a biopharmaceutical company focused on developing innovative medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer. With over three decades of breakthroughs, Gilead operates in more than 35 countries, headquartered in Foster City, California.
Gilead Sciences (GILD) announced the retirement of Brett Pletcher, Executive Vice President, Corporate Affairs, after 17 years. Deborah Telman will succeed him as Executive Vice President and General Counsel, effective August 1, 2022. Telman, who joins from Organon, brings over 25 years of legal experience and will oversee legal and corporate affairs. CEO Daniel O'Day praised Telman's leadership and commitment to health equity. Pletcher's tenure included significant contributions to Gilead's global expansion and health policy strategy.